Boehringer Ingelheim Pays $13.5M To Settle States’ Off-Label Drug Claims
NEW YORK — Drug manufacturer Boehringer Ingelheim Pharmaceuticals Inc. has agreed to pay all 50 states and the District of Columbia $13.5 million to resolve allegations that it engaged in deceptive...To view the full article, register now.
Already a subscriber? Click here to view full article